Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04271514 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
A Phase 1 study of Atopic Dermatitis, sponsored by RAPT Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 14
- Study locations
NCT04271514: Completed Phase 1 study of Atopic Dermatitis, sponsored by RAPT Therapeutics.
NCT04271514 is a Phase 1 study of Atopic Dermatitis that has completed, run by RAPT Therapeutics. The registered enrollment target is 103 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04271514, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by RAPT Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Primary Outcome
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPT193
Study Locations (14)
Florida
- Lenus Research & Medical Group - Miami
- ForCare Clinical Research - Tampa
Louisiana
- DelRicht Research - Baton Rouge
- Clinical Trials Management,LLC - Metairie
Texas
- DermResearch, Inc. - Austin
- Progressive Clinical Research PA - San Antonio
Alabama
- Pinnacle Research Group, LLC - Anniston
Arizona
- Perseverance Research Center LLC - Scottsdale
California
- University Clinical Trials, Inc - San Diego
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Massachusetts
- MetroBoston Clinical Partners LLC - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 1 |
What the finished NCT04271514 record still lists
NCT04271514 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04271514 lists 14 locations in 11 states (Florida, Louisiana, Texas).
Frequently Asked Questions
What is clinical trial NCT04271514 about?
NCT04271514 is a clinical study titled "A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis". This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
What is the current status of trial NCT04271514?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2019-08-12. Estimated completion is 2021-04-26.
What conditions does trial NCT04271514 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04271514?
The interventions under investigation include: Placebo (DRUG), RPT193 (DRUG).
Who is sponsoring clinical trial NCT04271514?
This trial is sponsored by RAPT Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04271514 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04271514's enrollment target sits among peer trials
103 83rd of 150 higher than 68 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI